Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAPTER-4 long-term deucrictibant prophylaxis in hereditary angioedema
2024-516248-24-00Phase 3Authorised
- Sponsor
- Pharvaris
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, open-label, single-arm trial of deucrictibant in hereditary angioedema type I (HAE-I), Hereditary Angioedema Type 2 (HAE2) and Hereditary Angioedema With Normal C1-Inhibitor (HAE-nl-C1-INH), sponsored by Pharvaris. Primary endpoints: Treatment-emergent adverse events, Clinical laboratory tests and 2 more. Planned start Mar 2025; status: authorised.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)Hereditary Angioedema With Normal C1-Inhibitor (HAE-nl-C1-INH)
Beyond the preview
Go deeper on 2024-516248-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516248-24-00.